Curevo, a Seattle, WA-based clinical-stage biotechnology company, raised $110M in Series B funding.
The round was led by Medicxi, with participation from OrbiMed, HBM Healthcare Investments, and Sanofi Ventures plus existing investors RA Capital Management, Janus Henderson Investors, Adjuvant Capital, and founding investor GC Biopharma. Concurrent with the round, Moncef Slaoui, PhD, will join Curevo as Board Chair. Also joining Curevo’s Board of Directors will be Giovanni Mariggi, PhD, co-founder and Partner at Medicxi. Tal Zaks, MD/PhD, will be joining the Board on behalf of OrbiMed.
The company intends to use the funds to accelerate the extension of its Phase 2 program into an additional 640 participants, including the key population of adults over age 70, to finalize dose selection ahead of the Phase 3 program.
Led by CEO George Simeon, Curevo is a clinical-stage biotechnology company dedicated to developing vaccines with improved tolerability and accessibility. Its lead product is amezosvatein, a non-mRNA adjuvanted sub-unit vaccine to prevent shingles, a serious medical condition involving a painful, blistering skin rash where 10-18% of people also develop serious, long-lasting nerve pain.
FinSMEs
17/03/2025
